Topical Aprepitant in Clinical and Experimental Pruritus | Dermatology | JAMA Dermatology | JAMA Network
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
JAMA Network Home
JAMA Dermatology
full text icon
Full Text
 contents icon
Contents
 figure icon
Figures /
Tables
 multimedia icon
Multimedia
 attach icon
Supplemental
Content
 references icon
References
 related icon
Related
 comments icon
Comments
1.
Duval A, Dubertret L. Aprepitant as an antipruritic agent?  N Engl J Med. 2009;361(14):1415-141619797294PubMedGoogle ScholarCrossref
2.
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues.  J Am Acad Dermatol. 2012;66(1):e14-e1522177649PubMedGoogle ScholarCrossref
3.
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.  PLoS One. 2010;5(6):e1096820532044PubMedGoogle ScholarCrossref
4.
Gerber PA, Buhren BA, Homey B. More on aprepitant for erlotinib-induced pruritus.  N Engl J Med. 2011;364(5):486-48721288112PubMedGoogle ScholarCrossref
5.
Wallengren J. Neuroanatomy and neurophysiology of itch.  Dermatol Ther. 2005;18(4):292-30316297000PubMedGoogle ScholarCrossref
6.
Hill R. NK1 (substance P) receptor antagonists—why are they not analgesic in humans?  Trends Pharmacol Sci. 2000;21(7):244-24610871891PubMedGoogle ScholarCrossref
7.
Mantyh PW. Neurobiology of substance P and the NK1 receptor.  J Clin Psychiatry. 2002;63:(suppl 11)  6-1012562137PubMedGoogle Scholar
This Issue
Views 2,894
Citations 17
View Metrics
Research Letter
Aug 2012

Topical Aprepitant in Clinical and Experimental Pruritus

Joanna Wallengren, MD, PhD
Author Affiliations Article Information

Author Affiliations: Department of Dermatology, Skane University Hospital, Lund, Sweden.

Arch Dermatol. 2012;148(8):957-959. doi:10.1001/archdermatol.2012.1018
visual abstract icon
Visual
Abstract
 editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia

Peroral aprepitant is a nonpeptide inhibitor of tachykinin receptor NK1 approved for use as an antiemetic drug for chemotherapy-induced nausea. Duval and Dubertret1 first reported that peroral aprepitant effectively reduced pruritus in 3 patients with Sézary syndrome. Similar results were obtained later for 6 of 7 patients with erythrodermic cutaneous T-cell lymphoma.2 Ständer et al3 reported an open-label study of 20 patients with chronic pruritus treated for a week with peroral aprepitant. It has been suggested that the effects of aprepitant are related to its preventing of mast-cell activation in the skin.4 The aim of the present study was to test this hypothesis with topical aprepitant.

×